RxDoctor Payments DataLook up a doctor →

Wissam Saliba, MD

Internal Medicine · Wichita, KSNPI 1104025949

Payments from drug & device makers

$157,039in general payments, 2019–2025

Across 455 payments — averaging $345.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$98K
  • Medtronic$29K
  • Travere Therapeutics, Inc.$12K
  • Amgen$11K
  • Novartis$3K
  • Calliditas Therapeutics US Inc.$493
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$6,9825%
  • Speaking & faculty fees$123,93380%
  • Travel & lodging$14,0149%
  • Food & beverage$9,4456%
  • Education$1870%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,039 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$522,235
Medicare patients
1,040
Services billed
5,310

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$149,036
KerendiaFinerenone70$94,089
AuryxiaFerric Citrate39$52,415
JardianceEmpagliflozin50$46,606
XphozahTenapanor Hcl11$33,757
VeltassaPatiromer Calcium Sorbitex15$29,294
EliquisApixaban14$11,510
Bumetanide229$9,147
Sevelamer Carbonate40$7,863
Calcium Acetate66$4,907
Potassium Chloride252$4,602
Potassium Citrate ErPotassium Citrate54$3,560
Calcitriol147$2,685
ProsolParenteral Amino Acid 20% No.122$2,333
Losartan Potassium308$2,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$279$149,036137 claims
BayerKerendia$97,747$94,08970 claims
Akebia Therapeutics IncAuryxia$206$52,41539 claims
Boehringer IngelheimJardiance$307$46,60650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →